Incidence rates of influenza illness during pregnancy in Suzhou, China, 2015–2018

Liling Chen1 | Suizan Zhou2 | Lin Bao1 | Alexander J. Millman2 | Zhongwei Zhang3 | Yan Wang4 | Yayun Tan1 | Ying Song2 | Pengwei Cui1 | Yuanyuan Pang1 | Cheng Liu1 | Jiangchun Qin1 | Ping Zhang1 | Mark G. Thompson2 | A. Danielle Iuliano2 | Ran Zhang2 | Carolyn M. Greene2 | Jun Zhang1

1Suzhou Center for Disease Control and Prevention, Suzhou, China
2U.S. Centers for Disease Control and Prevention, Atlanta, GA, USA
3Suzhou Municipal Hospital, Suzhou, China
4Wuzhong Maternal and Child Health Care Institute, Suzhou, China

Correspondence
Jun Zhang, Suzhou Center for Disease Control and Prevention, 72 Sanxiang Road, Suzhou 215004, China.
Email: sz_zhang@163.com

Funding information
Suzhou Commission of Health, Grant/Award Numbers: KJXW2017054, Sxk201516; Suzhou Municipal Science and Technology Bureau, Grant/Award Number: SS202073; Jiangsu Commission of Health; United States Centers for Disease Control and Prevention, Grant/Award Number: 5U2GGH000018

Background: Data on influenza incidence during pregnancy in China are limited.

Methods: From October 2015 to September 2018, we conducted active surveillance for acute respiratory illness (ARI) among women during pregnancy. Nurses conducted twice weekly phone and text message follow-up upon enrollment until delivery to identify new episodes of ARI. Nasal and throat swabs were collected ≤10 days from illness onset to detect influenza.

Results: In total, we enrolled 18 724 pregnant women median aged 28 years old, 37% in first trimester, 48% in second trimester, and 15% in third trimester, with seven self-reported influenza vaccination during pregnancy. In the 18-week epidemic period during October 2015 to September 2016, influenza incidence was 0.7/100 person-months (95% CI: 0.5–0.9). In the cumulative 29-week-long epidemic during October 2016 to September 2017, influenza incidence was 1.0/100 person-months (95% CI: 0.8–1.2). In the 11-week epidemic period during October 2017 to September 2018, influenza incidence was 2.1/100 person-months (95% CI: 1.9–2.4). Influenza incidence was similar by trimester. More than half of the total influenza illnesses had no elevated temperature and cough. Most influenza-associated ARIs were mild, and <5.1% required hospitalization.

Conclusions: Influenza illness in all trimesters of pregnancy was common. These data may help inform decisions regarding the use of influenza vaccine to prevent influenza during pregnancy.

KEYWORDS
active surveillance, cohort, incidence rate, influenza, pregnant women
1 | INTRODUCTION

Pregnant women are known to be at risk for severe influenza disease and influenza-associated morbidity and mortality. During the 2009 influenza pandemic, influenza illnesses were observed to be associated with complications during pregnancy including maternal mortality and loss of pregnancy. The World Health Organization (WHO) and national public health authorities have recommended vaccination, the best tool for preventing influenza illness and complications associated with infection, for high risk groups including for pregnant women. However, despite recommendation from the Chinese Center for Disease Control and Prevention (China CDC), seasonal influenza vaccination coverage during pregnancy in China is less than 1%. In China, there are significant barriers to promoting seasonal influenza vaccination in pregnant women including an absolute contraindication for this population in the Chinese Pharmacopeia until the latest revision in 2020, healthcare worker reluctance to recommend this vaccination to pregnant women, and women’s concerns about vaccine safety or lack of awareness of vaccination. Knowledge of influenza infection during pregnancy is also limited. Previous studies found that only 20% of surveyed pregnant women were aware that influenza infection could cause serious harm during pregnancy and 61% reported an interest in learning about prevention and control of influenza.

Data are needed to evaluate burden of influenza virus infection during pregnancy in China, to enhance risk communication and to inform future prevention and control measures including increasing influenza vaccine uptake within this population. We conducted active surveillance among pregnant women in Suzhou, China, to assess influenza incidence in a population at risk for influenza disease.

2 | METHODS

2.1 | Study design and participants

From October 2015 to September 2018, we conducted active surveillance for laboratory-confirmed influenza-associated acute respiratory illness (ARI) among pregnant women in Suzhou. Suzhou is a city located in eastern China with an estimated population of approximately 10 million in 2015. Influenza surveillance data from Suzhou and similar geographic areas have demonstrated semi-annual seasonal patterns with peak activity typically occurring in January–February and June–August.

The enrollment methodology and description of the cohort profile of the China Respiratory Illness Surveillance among Pregnant women (CRISP) have been published previously. In brief, from October 2015 to September 2018, nurses consented and enrolled pregnant women in different trimesters of pregnancy (first trimester defined as 1–12 weeks gestation, second as 13–26 weeks gestation, and third as 27 weeks to gestation) from two prenatal care facilities that provide prenatal care services to 17% of women residing in Suzhou during pregnancy and one pre-marriage health center. Prenatal care facilities were selected as enrollment sites because more than 95% of pregnant women who had a live birth or stillbirth delivery after 28 weeks gestation in Suzhou had made at least one prenatal care visit at a prenatal care facility and because pregnancy status would be confirmed by ultrasound as part of routine care. We selected a pre-marriage health center, which offers pregnancy testing to couples, as an enrollment site to identify women who may have been early in their pregnancies. Pregnant women who lived in and planned to deliver in Suzhou were considered eligible for enrollment. Pregnant women who sought non-routine prenatal care such as confirmation of low progesterone and threatened miscarriage were excluded.

2.2 | Enrollment of the annual cohort

Study nurses enrolled pregnant women into annual cohorts from October to September of each study year that was defined as the influenza season in the national influenza surveillance protocol. Most individuals in each cohort were enrolled before November. However, to ensure enrollment of adequate numbers of first trimester pregnant women and to ensure sufficient numbers of pregnant women to follow during the summer, we continuously enrolled first trimester pregnant women from the October–September period, which allowed us continuous observations throughout the year (Figure 1).

Upon enrollment, study nurses conducted face-to-face interviews using a structured questionnaire to collect data on the participant’s demographics, health conditions, pregnancy-associated conditions, health behaviors, social behaviors, and self-reported influenza vaccination status. For health conditions, chronic diseases referred to any medical problem diagnosed by a doctor or other health care provider before pregnancy that lasted for at least 6 months such as diabetes, asthma, heart disease, or cancer. Pregnancy-associated conditions referred to a newly developed condition identified during pregnancy by enrollment such as gestational diabetes or high blood pressure. Health and social behaviors included dietary supplement intake, smoking, alcohol, and self-reported changes in working hours and social activities.

2.3 | Follow-up for ARI episodes and laboratory testing

After enrolling pregnant women in active surveillance, study nurses conducted twice weekly follow-up starting at the enrollment date until the delivery date or the end of pregnancy/loss of pregnancy with phone call and WeChat text message (a free, instant messaging application widely used in China) alternatively to identify episodes of ARI. An ARI episode was defined as ≥1 respiratory symptom (cough, sore throat, stuffy nose, chest pain, and difficulty breathing) and ≥1 systemic symptom (feverish, temperature ≥38°C, chills, and headache) or ≥2 respiratory symptoms. When a current illness or recent illness was identified, the study nurse used a standardized questionnaire to
collect data on illness onset date, symptoms, and hospital admission. Participants reporting ARI were encouraged to visit the study hospital’s respiratory illness department (ambulatory clinics) or offered a house call for testing to ensure specimen collection ideally within 24 h but up to a maximum 10 days from illness onset. Study nurses collected both a nasal and a throat swab with double-headed disposable virus sampling tube (YOCON Biology Technology Company, Beijing). Respiratory specimens were transported to the Suzhou CDC laboratory within 24 h of collection at 4°C and were analyzed using real-time reverse transcription polymerase chain reaction to test for influenza virus subtype/lineage.

2.4 | Data analysis

The cohorts were considered open, and eligible participants could be enrolled at any time during the study period. An enrolled participant was considered to have complete data if she completed the enrollment interview, responded to weekly surveillance contacts by study nurses until delivery or termination of pregnancy, and had perinatal records available for review. Those who were lost to follow-up (no response to any contact for at least two consecutive weeks despite multiple attempts), voluntarily withdrew, or left Suzhou before the end of pregnancy only contributed the person-time for which there was available data. If a pregnant woman was enrolled in an annual cohort but delivered after the end of the surveillance year, the person-time was split between the two surveillance years. For example, if a woman was enrolled at week 10 of pregnancy and 15 weeks of her remaining pregnancy occurred in one surveillance year and the other 15 occurred in the following surveillance year, we considered 15 weeks of person-time to have occurred in surveillance year 1 and 15 weeks of person-time to have occurred in surveillance year 2. To streamline cohort management and reporting, the full analytic population for each surveillance year included those contributing person-time from the previous surveillance year if applicable.

We calculated incidence rate over the influenza epidemic periods of each influenza surveillance year. The start of each influenza epidemic period was defined as the first day of three consecutive influenza reporting weeks in which the percentage of specimens testing positive for any influenza virus infection was higher than 5%. The end of each influenza epidemic period was defined as the day before the first of three consecutive influenza reporting weeks in which the percentage of specimens testing positive for influenza was below 5%. In the influenza incidence rates calculation, illness episodes were considered as distinct episodes if they occurred at least 2 weeks apart, from the end of symptoms for one episode to the onset of any new symptom, and the population at risk was defined as women pregnant for 2 weeks or more during the epidemic period.

Our primary outcome was the influenza incidence identified through ARI screening. For secondary outcomes, we evaluated the influenza incidence using influenza-like illness (ILI) case definitions for screening. ILI was defined as a measured temperature ≥38°C and cough/sore throat.

We described demographic, clinical, and knowledge and practices related to influenza vaccination. Chi-square or Fisher exact tests were used to compare proportions where appropriate. Incidence rate was
calculated as the number of new cases per 100 person-month. Since the total number of missed swabs was minimal, those with missing swabs contributed person time but did not contribute to the total number of influenza positive cases; 95% confidence interval (CI) for person-month rate was simulated with bootstrapping. Fisher exact test was used to compare person-month rates. All tests were two sided, and a \( p < 0.05 \) was considered as statistically significant. R version 3.5.3 was used for statistical analysis.

3 | RESULTS

3.1 | Cohort characteristics

Among the women registered for prenatal care or with positive pregnancy tests in study facilities, we had high contact rates (reached) of 97% (6489/6661), 99% (8993/9116), and 98% (6779/6892) over three cohorts, respectively. Among those reached, 84% (18 724/22 261) participated in the prospective cohorts with participation rates of 87% (5636/6489) in year 1 cohort, 80% (7226/8993) in year 2 cohort, and 86% (5862/6779) in year 3 cohort. Among participants, 95% (17 871/18 724) had complete follow-up information until delivery with minimal variability by cohort year. Most participants who did not complete follow-up either left Suzhou (2%, 291/18 724), voluntarily withdrew (1%, 277/18 724), or were lost to follow-up (2%, 285/18 724) (Figure 2).

Among all 18 724 enrolled participants, the median age was 28 years old, and 73% reported college or higher level of education. At enrollment, 37% were in the first trimester, 48% were in the second trimester, and 15% were in the third trimester. Among participants, 3% reported a previously diagnosed chronic disease, and 1% reported a pregnancy-associated medical condition by enrollment. Among the 18 724 pregnant women, 2918 (18%) who reported not working in the week prior to enrollment, pregnancy...
was the self-reported primary reason among 86% for not working. Of all participants, 40% reported decreased working hours during pregnancy, 52% reported a reduction in general social interactions, and 57% reported reduced social activities with friends during pregnancy (Table 1).

Of the 18,724 women, 61% reported knowing of influenza vaccination. Only 7/18,724 (0%) reported that they had been vaccinated during pregnancy. Only 0.6% reported influenza vaccination in the prior year and 0.6% reported influenza vaccination among family members in the prior year. The proportion vaccinated during pregnancy did not differ significantly across cohorts (Table 1).

### 3.2 | Influenza incidence

From October 2015 to September 2016, we followed participants for a total of 22,125 person-months, with an average of 3.9 months for each participant and a standard deviation (SD) of 2.5 months. In 2015/2016, we collected samples for 83% of the 1,429 ARIs reported. Of those, 67 (6%) were influenza positive. The influenza epidemic period for this season was 18 weeks from Week 53, 2015, to Week 17, 2016, with an influenza incidence of 0.7/100 person-months (95% CI: 0.5–0.9), and A(H1N1)pdm09 virus most frequently detected (Table 2, Figure 3).

From October 2016 to September 2017, we observed a total of 25,775 person-months, with an average of 3.6 months for each participant (SD 2.6). In 2016/2017, 98% of 2,637 ARIs reported had samples collected. Of those, 185 samples (7%) were influenza positive. The influenza incidence during the total 29-week long epidemic with two separate periods from Week 47, 2016, to Week 13, 2017, and from Week 30, 2017, to Week 39, 2017, was 1.0/100 person-months (95% CI: 0.8–1.2), and A(H3N2) virus was most frequently detected (Table 2, Figure 3).

From October 2017 to September 2018, we observed a total of 27,102 person-months, with an average of 4.6 months for each participant (SD 2.2). In 2017/2018, of 2,402 ARI reported, 96% had samples collected. Of those, 225 samples (10%) were influenza positive. The influenza incidence during the 11-week epidemic period, from Week 52, 2017, to Week 10, 2018, was 2.1/100 person-months (95% CI: 1.9–2.4), with B virus Yamagata lineage most frequently detected (Table 2, Figure 3).

### 3.3 | Factors associated with the incidence estimates

No significant difference in influenza incidence was observed by age or education level. Influenza incidence varied significantly when using different surveillance case definitions. Using ILI as the surveillance case definition had significantly lower influenza incidence (0.4 per 100 person-months) than using ARI (1.2 per 100 person-months) in overall of the epidemic periods (p < 0.001). The findings regarding demographic characteristics and case definitions’ difference in influenza illnesses were consistent over the entire study period (Table 2). These findings were also consistent when expanding the observation outside of the epidemic period (data not shown).

In the overall cohort, ARI incidence decreased significantly in the second trimester (10.0 per 100 person-months) and in the third trimester (7.6 per 100 person-months) in comparison with the first trimester (21.0 per 100 person-months) during the epidemic periods (Table 3). This observation was consistent in all three cohorts. However, in the overall cohort, we found no significant differences in the influenza incidence by trimester, which was 1.4 per 100 person-months during the first trimester and 1.2 per 100 person-months during both the second and third trimesters. Within the three cohorts, influenza incidence did not differ by trimester in the 2015/2016 and 2016/2017 cohorts, while in the 2017/2018 cohort, the influenza incidence for women in the third trimester (2.0 per 100 person-months) was significantly lower compared with the influenza incidence in the first trimester (3.8 per 100 person-months). As is shown in Table 3, among influenza-associated ARIs in the three annual cohorts, three of 66 (4.5%), eight of 158 (5.1%), and three of 187 (1.6%) required hospitalization during epidemic period. Overall, compared with first (0%) trimester and second (0.7%) trimester, influenza-associated ARIs in the third (5.4%) trimester were more frequently hospitalized.

### 4 | DISCUSSION

From 2015 to 2018, influenza incidence during epidemic periods in pregnant women varied by year ranging from 0.7 to 2.1 per 100 person-months. Influenza vaccination during pregnancy was rare although approximately half of the women enrolled reported social distancing behavioral changes during pregnancy. Influenza incidence was similar across trimesters. Using ILI as a case definition missed more than half of the total influenza illnesses compared with broader ARI criteria. Over the three cohorts, 1.6–5.1% of influenza-associated ARI cases required hospitalization.

Prior to this study, there were limited data on influenza incidence and epidemiology of infection during pregnancy in China. By following cohorts of pregnant women over multiple seasons using a sensitive case definition and highly sensitive and specific molecular diagnostics, we found that during influenza epidemic periods in 2015–2018 in Suzhou, women were frequently infected with influenza during pregnancy and in some cases had illness requiring hospitalization. Our estimated influenza incidence rates were similar with a prospective cohort study in three middle income countries that showed women had a 0.7–0.9% risk of influenza per month of pregnancy during the 2017–2018 influenza seasons. Our incidence estimates were higher than influenza incidence rates observed in influenza vaccination clinical trials in other low and middle income countries. One reason for this difference was that unlike some other studies, our case definition included non-febrile influenza illnesses. Requiring the presence of measured fever in the case definition as with ILI substantially reduced the number of
### TABLE 1 Characteristics of the annual cohorts of China Respiratory Illness Surveillance among Pregnant Women (CRISP), Suzhou, 2015/2016–2017/2018 seasons

|                      | 2015/2016 cohort (N = 5636) | 2016/2017 cohort (N = 7226) | 2017/2018 cohort (N = 5862) | Overall (N = 18 724) |
|----------------------|-----------------------------|-----------------------------|-----------------------------|----------------------|
| **Demographics**     |                             |                             |                             |                      |
| Age                  |                             |                             |                             |                      |
| <25 y                | 937/5636 (17)               | 1014/7216 (14)              | 818/5862 (14)               | 2769/18 714 (15)     |
| 25–29 y              | 3183/5636 (56)              | 3747/7216 (52)              | 3033/5862 (52)              | 9963/18 714 (53)     |
| 30–34 y              | 1181/5636 (21)              | 1798/7216 (25)              | 1488/5862 (25)              | 4467/18 714 (24)     |
| ≥35 y                | 335/5636 (6)                | 657/7216 (9)                | 523/5862 (9)                | 1515/18 714 (8)      |
| Han ethnicity        | 5494/5549 (97)              | 7119/7188 (99)              | 5764/5824 (98)              | 18 377/18 561 (99)   |
| Suzhou permanent residency registration | 2910/5587 (52) | 3890/7193 (54) | 2997/5828 (51) | 9797/18 608 (53) |
| College or higher education | 4094/5619 (73) | 5340/7196 (74) | 4229/5862 (72) | 13 663/18 643 (73) |
| **Trimester at enrollment** |                  |                             |                             |                      |
| First (<13 gestational weeks) | 1407/5636 (25) | 3114/7226 (43) | 2408/5862 (41) | 6929/18 724 (37)     |
| Second (13–27 gestational weeks) | 3052/5636 (54) | 3271/7226 (45) | 2659/5862 (45) | 8982/18 724 (48)     |
| Third (≥28 gestational weeks) | 1177/5636 (21) | 841/7226 (12) | 795/5862 (14) | 2813/18 724 (15)     |
| **Medical history**  |                             |                             |                             |                      |
| Underlying chronic disease | 153/5636 (3) | 170/7226 (2) | 149/5862 (3) | 472/18 724 (3) |
| Newly diagnosed condition during pregnancy | 98/5636 (2) | 76/7226 (1) | 91/5862 (2) | 265/18 724 (1) |
| **Health behaviors** |                             |                             |                             |                      |
| Take vitamins, minerals or other dietary supplements before pregnancy | 2437/5514 (44) | 3905/7126 (55) | 2865/5759 (50) | 9207/18 399 (50) |
| Take vitamins, minerals or other dietary supplements during pregnancy | 3956/5521 (72) | 5523/7148 (77) | 4412/5780 (76) | 13 891/18 449 (75) |
| Have ever used or taken any medication during pregnancy | 537/5490 (10) | 495/7151 (7) | 464/5794 (8) | 1496/18 435 (8) |
| Ever smoked | 52/5606 (0.9) | 38/7175 (0.5) | 27/5825 (0.5) | 117/18 606 (0.6) |
| During the past 7 days, a household member smoked tobacco in your presence | 366/5636 (6) | 221/7226 (3) | 220/5862 (4) | 807/18 724 (4) |
| During the past 7 days, a colleague smoked tobacco in your presence | 213/5636 (4) | 142/7226 (2) | 114/5862 (2) | 469/18 724 (3) |
| During the past month, consumed an alcoholic beverage at least once (including beer, wine, and other liquor) | 59/5590 (1) | 65/7175 (1) | 43/5825 (1) | 167/18 590 (1) |
| **Social behaviors** |                             |                             |                             |                      |
| Not working in the entire prior week | 1109/4931 (22) | 952/6211 (15) | 857/5065 (17) | 2918/16 207 (18) |
| Pregnancy as the reason for being not working | 941/1065 (88) | 813/945 (86) | 715/5858 (83) | 2469/2868 (86) |
| Reduced work hours since aware of pregnancy | 1988/4738 (42) | 2534/6204 (41) | 1930/5065 (38) | 6452/16 007 (40) |
| Reduced general social interactions since pregnancy | 2804/5588 (50) | 3846/7173 (54) | 3040/5824 (52) | 9690/18 585 (52) |
| Reduced social activities with friend | 3528/5595 (63) | 4107/7177 (57) | 3042/5825 (52) | 10 677/18 597 (57) |
| **Influenza vaccination** |                             |                             |                             |                      |
| Ever heard of influenza vaccine | 3897/5636 (69) | 4562/7226 (63) | 3054/5862 (52) | 11 513/18 724 (61) |
| Vaccinated in the prior 1 year | 44/5636 (0.8) | 32/7226 (0.4) | 32/5862 (0.5) | 108/18 724 (0.6) |
| Vaccinated during pregnancy | 2/5636 (0.0) | 1/7226 (0.0) | 4/5862 (0.0) | 7/18 724 (0.0) |
| Any vaccination in family members | 22/5636 (0.4) | 21/7226 (0.3) | 74/5862 (1.3) | 117/18 724 (0.6) |

Note: Data were n/N (%).

*Chronic disease refers to any medical problem diagnosed by a doctor or other health care provider before pregnancy that lasted for at least six months such as diabetes, asthma, heart disease, or cancer.

Newly diagnosed condition during pregnancy: pregnancy induced new health problems or diseases such as diabetes, high blood pressure diagnosed during pregnancy.

Changes in denominator reflect missing data or refusal to answer.
influenza-associated illness detected during pregnancy in Suzhou. This finding of lack of febrile illness among influenza infected pregnant patients is consistent with previously described findings from the United States in this population. Thus, our study, the first to describe influenza illness during pregnancy in China, also demonstrated the importance of including non-febrile illness to identify influenza infection and accurately estimate symptomatic influenza incidence in this population.

Although we found that the incidence of ARI during pregnancy varied by trimester, in our cohort, influenza incidence was similar

### TABLE 2  Influenza incidence during the epidemic periods in the annual cohorts of China respiratory illness surveillance among pregnant women (CRISP), Suzhou, 2015/2016–2017/2018 seasons (per 100 person-months)

| Syndrome          | 2015/2016 | 2016/2017 | 2017/2018 | Overall incidence |
|-------------------|-----------|-----------|-----------|-------------------|
|                   | Rate (95% CI) | p | Rate (95% CI) | p | Rate (95% CI) | p | Rate (95% CI) | p |
| ARI influenza by age at enrollment |             |           |           |                  |           |           |           |                  |           |           |           |                  |           |           |           |                  |           |           |
| <25 y             | 0.6 (0.3, 1.0) | REF | 0.8 (0.4, 1.3) | REF | 2.4 (1.6, 3.2) | REF | 1.1 (0.8, 1.5) | REF |
| 25–29y            | 0.6 (0.4, 0.8) | 1.000 | 1.1 (0.9, 1.3) | 0.362 | 2.0 (1.6, 2.4) | 0.559 | 1.2 (1.0, 1.3) | 0.885 |
| 30–34y            | 1.0 (0.5, 1.4) | 0.354 | 0.9 (0.6, 1.2) | 0.960 | 2.1 (1.6, 2.7) | 0.741 | 1.3 (1.0, 1.5) | 0.618 |
| 35y               | 0.4 (0.0, 1.0) | 0.864 | 1.1 (0.6, 1.7) | 0.539 | 2.3 (1.2, 3.4) | 1.000 | 1.3 (0.9, 1.7) | 0.613 |
| ARI influenza by education level |             |           |           |                  |           |           |           |                  |           |           |           |                  |           |           |           |                  |           |           |
| Junior high school (9th grade) or lower | 0.8 (0.3, 1.5) | REF | 0.9 (0.3, 1.6) | REF | 2.7 (1.7, 3.8) | REF | 1.5 (1.0, 2.0) | REF |
| Senior high school (12th) | 0.7 (0.3, 1.1) | 0.897 | 1.3 (0.9, 1.7) | 0.504 | 2.6 (1.9, 3.4) | 0.948 | 1.5 (1.2, 1.8) | 1.000 |
| College or higher  | 0.7 (0.5, 0.9) | 0.732 | 1.0 (0.8, 1.1) | 1.000 | 1.9 (1.6, 2.3) | 0.181 | 1.1 (1.0, 1.2) | 0.100 |
| Syndrome          | 2015/2016 | 2016/2017 | 2017/2018 | Overall incidence |
|                   | Rate (95% CI) | p | Rate (95% CI) | p | Rate (95% CI) | p | Rate (95% CI) | p |
| ARIb              | 0.7 (0.5, 0.9) | REF | 1.0 (0.8, 1.2) | REF | 2.1 (1.9, 2.4) | REF | 1.2 (1.1, 1.3) | REF |
| IILc              | 0.3 (0.2, 0.4) | <0.001 | 0.3 (0.2, 0.4) | <0.001 | 0.6 (0.4, 0.7) | <0.001 | 0.4 (0.3, 0.5) | <0.001 |

Abbreviations: CI, confidence interval; NA, not applicable; REF, reference.

- The start of each influenza epidemic period was defined as the first day of three consecutive influenza reporting weeks in which the percentage of specimens testing positive for any influenza virus infection was higher than 5%. The end of each influenza epidemic period was defined as the day before the first of three consecutive influenza reporting weeks in which the percentage of specimens testing positive for influenza was below 5%.
- ARI: acute respiratory illness, defined as ≥1 respiratory symptom (cough, sore throat, stuffy nose, chest pain, and difficulty breathing) and ≥1 systemic symptom (feverish, temperature ≥38°C, chills, headache); or ≥2 respiratory symptoms with onset within the last 10 days.
- IIL: influenza-like illness, defined as a measured temperature ≥38°C and cough/sore throat with onset within the last 10 days.

![FIGURE 3](image-url)  
**FIGURE 3** Number of laboratory-confirmed influenza illnesses by subtype/lineage and monthly incidence in the annual cohorts of China Respiratory Illness Surveillance among Pregnant Women (CRISP), Suzhou, 2015/2016–2017/2018 seasons
Acute respiratory illness (ARI), influenza illness and influenza hospitalization during the epidemic period by the trimester of symptom onset in the annual cohorts of China respiratory illness surveillance among pregnant women (CRISP), Suzhou, 2015/2016–2017/2018 seasons.

|                      | ARI incidence (per 100 person-months, 95% CI) | p   | Influenza incidence (per 100 person-months, 95% CI) | p   | Influenza hospitalization, n/N (% of influenza ARI) | p   |
|----------------------|---------------------------------------------|-----|------------------------------------------------------|-----|----------------------------------------------------|-----|
| Overall              |                                             |     |                                                      |     | 13/411 (3.2)                                       |     |
|                      | First                                       | 21.0 (19.5, 22.6) | REF | 1.4 (1.0, 1.9) | REF | 0/39 (0.0) | REF |
|                      | Second                                      | 10.0 (9.5, 10.5) | <0.001 | 1.2 (1.0, 1.4) | 0.419 | 1/151 (0.7) |     |
|                      | Third                                       | 7.6 (7.2, 7.9) | <0.001 | 1.2 (1.0, 1.3) | 0.333 | 12/221 (5.4) | 0.005 |
| 2015/2016            |                                             |     |                                                      |     | 3/66 (4.5)                                       |     |
|                      | First                                       | 17.6 (15.3, 20.0) | REF | 0.7 (0.2, 1.3) | REF | 0/6 (0.0) | REF |
|                      | Second                                      | 8.3 (7.4, 9.4) | <0.001 | 0.7 (0.4, 1.0) | 1.000 | 0/22 (0.0) |     |
|                      | Third                                       | 6.3 (5.7, 6.9) | <0.001 | 0.7 (0.5, 0.9) | 0.941 | 3/38 (7.9) | 0.256 |
| 2016/2017            |                                             |     |                                                      |     | 8/158 (5.1)                                       |     |
|                      | First                                       | 22.8 (20.6, 24.9) | REF | 1.2 (0.6, 1.8) | REF | 0/17 (0.0) | REF |
|                      | Second                                      | 11.2 (10.3, 11.8) | <0.001 | 1.0 (0.7, 1.2) | 0.527 | 0/59 (0.0) |     |
|                      | Third                                       | 8.4 (7.8, 9.0) | <0.001 | 1.0 (0.8, 1.3) | 0.728 | 8/82 (9.8) | 0.007 |
| 2017/2018            |                                             |     |                                                      |     | 3/187 (1.6)                                       |     |
|                      | First                                       | 22.6 (18.6, 26.7) | REF | 3.8 (2.1, 5.6) | REF | 0/16 (0.0) | REF |
|                      | Second                                      | 9.5 (8.5, 10.5) | <0.001 | 2.1 (1.7, 2.6) | 0.063 | 1/70 (1.4) |     |
|                      | Third                                       | 7.7 (7.0, 8.4) | <0.001 | 2.0 (1.6, 2.4) | 0.032 | 2/101 (2.0) | 1.000 |

Abbreviations: CI, confidence interval; REF, reference.

1. Acute respiratory illness (ARI) defined as ≥1 respiratory symptom (cough, sore throat, stuffy nose, chest pain, and difficulty breathing) and ≥1 systemic symptom (feverish, temperature ≥38°C, chills, headache) or ≥2 respiratory symptoms with onset within the last 10 days.

2. The start of each influenza epidemic period was defined as the first day of three consecutive influenza reporting weeks in which the percentage of specimens testing positive for influenza was below 5%. The end of each influenza epidemic period was defined as the day before the first of three consecutive influenza reporting weeks in which the percentage of specimens testing positive for influenza was higher than 5%.

Across trimesters, studies from the United States during the 2009 influenza pandemic described a higher frequency of hospitalization among pregnant women with influenza virus illness in the third trimester. Studies evaluating seasonal influenza hospital admission and rates of influenza outpatient visits in pregnant women have not observed differences by trimester. Our study’s active surveillance of community-dwelling pregnant women allowed us to develop a complete picture of ARI and influenza illness during pregnancy by trimester and, unlike prior studies, did not rely on participant health-seeking or clinician behavior for case identification. In our study, risk of influenza virus infection among pregnant women was similar throughout all trimesters of pregnancy, underscoring the importance of implementing measures such as influenza vaccination to prevent influenza-associated illness during all trimesters.

Applying the overall cohort influenza incidence rates during pregnancy of our study to a 12-week-long epidemic period, our result is comparable with the estimates in unvaccinated adults aged 18–64 years based on a modeling study from the United States, which estimated a cumulative seasonal incidence of symptomatic influenza of 4.3%–7.9% in seasons of moderate severity. Our findings show that women during pregnancy had similar risk of influenza illness compared with the general adult population. Furthermore, we found that only 1.6–5.1% of influenza-associated ARI cases were attributable to influenza vaccination, which is comparable with the estimates in unvaccinated adults aged 20–64 years based on a modeling study from the United States, which found a 0.7% case-hospitalization ratio (183 320 hospitalization in total 27 168 060 cases) in adults aged 20–64 years. Interestingly, although the 2017/2018 cohort had the highest proportion of influenza-associated ARI of the three surveillance years, the influenza-associated ARI hospitalization proportion was the lowest. As the 2017/2018 influenza season in China had the highest proportion of ILL since the 2009 pandemic, it is possible that pregnant women without underlying conditions were more likely to be treated as outpatients in the setting of increased demand for hospital beds.

Few participants in our cohort reported receiving an influenza vaccination during their pregnancy or in the year prior to their pregnancy. This finding is consistent with other published data from China, which showed that 0.2% of participants reported influenza vaccination within the last 12 months, and none during pregnancy. During the time of these studies, pregnancy was listed as a contraindication for seasonal influenza vaccination in the Chinese Pharmacopoeia and the vaccine package insert. Although removed from the China pharmacopoeia in 2020, this contraindication continues to be listed on the package insert. Despite the lack of influenza vaccination, 40–60% of participants reported social distancing behavioral modifications including reduction in work hours and social interactions during pregnancy. While there may be reasons beyond influenza prevention that our population engaged in these behavioral changes, a previous
Knowledge, Attitudes, and Practices study among pregnant women in China found that barriers to influenza vaccination included low perceived susceptibility to influenza and preference for non-pharmaceutical interventions to prevent infections.\textsuperscript{37} Our study demonstrates that despite behavioral modifications and perceptions, women remain susceptible to influenza virus infection during pregnancy and illness episodes may require hospitalization in even otherwise healthy individuals. Our findings highlight the importance of educating pregnant women on the benefits of influenza vaccination and addressing barriers to vaccinating pregnant women in China.

Our study had several strengths. First, this prospective cohort used laboratory-confirmed influenza as the outcome allowing us to identify respiratory disease incidence specific to influenza. Second, the study cohort had high participation and sample collection rates compared with similar studies,\textsuperscript{38} which reduced the likelihood of selection bias. Twice weekly follow-up contacts facilitated the rapid detection of illness episodes and aided in sampling respiratory viruses close to illness onset. Third, use of prenatal care facilities to recruit pregnant women enabled easy enrollment of the target population. Finally, the use of WeChat, a popular social mobile application, for active surveillance likely contributed to the high contact and retention rates.\textsuperscript{12}

This study was subject to several limitations. First, our surveillance case definitions do not capture atypical and asymptomatic manifestations of influenza infection. Second, our cohort only describes influenza incidence during pregnancy, so we are unable to compare the findings from this population to other high-risk populations or healthy women of child-bearing age. Finally, Suzhou is an economically developed city in China, and the participants in our cohort were older and had higher education levels compared to pregnant women in Suzhou overall\textsuperscript{12}; our study population may not be representative of pregnant women in rural areas of Jiangsu Province or other provinces in China.

5 | CONCLUSIONS

Influenza illnesses in all trimesters of pregnancy were common in Suzhou, China, and we found that non-febrile influenza illnesses were more frequent than febrile influenza illnesses during pregnancy. Pregnant woman in China are not getting vaccinated for seasonal influenza, and other studies have shown that barriers to vaccination include pregnancy listed as a contraindication in package insert, self-perceptions that they are not at risk of infection and healthcare worker reluctance to vaccinating this population.\textsuperscript{16} These data can support risk communication and may help promote effective prevention and control measures for influenza including vaccination during pregnancy.

ACKNOWLEDGMENTS

This work was supported by the Cooperative Agreement Number, 5U2GGH000018, funded by the United States Centers for Disease Control and Prevention; 2017 Scientific Research Project of Jiangsu Commission of Health; The Livelihood Science and Technology Projects of Suzhou Municipal Science and Technology Bureau (SS202073); Suzhou Medical Key Discipline Project and Science & Education Project of Suzhou Commission of Health (Szxk201516 and KJXW2017054).

CONFLICT OF INTERESTS

No conflict of interest declared.

ETHICS STATEMENT

This study was approved by the Institutional Review Board (IRB) of Jiangsu Provincial Center for Disease Control and Prevention and the United States (U.S.) Centers for Disease Control and Prevention relied upon the Jiangsu Provincial IRB.

AUTHOR CONTRIBUTIONS

Liling Chen: Data curation; formal analysis; methodology; project administration; software; supervision; visualization. Suzian Zhou: Conceptualization; methodology; project administration; validation; visualization. Lin Bao: Data curation; investigation; project administration; supervision. Alexander J. Millman: Formal analysis; methodology; validation; visualization. Zhongwei Zhang: Data curation; investigation; resources; supervision; visualization. Yan Wang: Data curation; investigation; resources; supervision; visualization. Yayun Tan: Data curation; formal analysis. Ying Song: Methodology; validation; visualization. Pengwei Cui: Data curation; formal analysis. Yuanyuan Pang: Data curation; investigation; supervision. Cheng Liu: Data curation; investigation; supervision. Jiangchun Qin: Data curation; investigation; supervision. Ping Zhang: Data curation; investigation; supervision. Mark G. Thompson: Formal analysis; methodology; visualization. A. Danielle Iuliano: Formal analysis; methodology; visualization. Ran Zhang: Methodology; project administration; validation; visualization. Carolyn M. Greene: Conceptualization; methodology; validation; visualization. Jun Zhang: Funding acquisition; methodology; project administration; software; visualization.

DISCLAIMER

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

PEER REVIEW

The peer review history for this article is available at https://publons.com/publon/10.1111/irv.12888.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID

Liling Chen https://orcid.org/0000-0002-2868-741X
REFERENCES

1. Goodnight W, Soper D. Pneumonia in pregnancy. Crit Care Med. 2005;33:390-397.
2. Laibl VR, Sheffield JS. Influenza and pneumonia in pregnancy. Clin Perinatol. 2005;32(3):727-738.
3. Rasmussen SA, Jamieson DJ, Uyeki TM. Effects of influenza on pregnant women and infants. Am J Obstet Gynecol. 2012;207(3):53-58.
4. Mertz D, Geraci J, Winkup J, Gessner BD, Ortiz JR, Loeb M. Pregnancy as a risk factor for severe outcomes from influenza virus infection: a systematic review and meta-analysis of observational studies. Vaccine. 2017;35(4):521-528.
5. Doyle TJ, Goodkin K, Hamilton JJ. Maternal and neonatal outcomes among pregnant women with 2009 Pandemic Influenza A(H1N1) illness in Florida, 2009–2010: a population-based cohort study. Plos One. 2013;8:e79040.
6. Jamieson DJ, Honein MA, Rasmussen SA, et al. H1N1 2009 influenza virus infection during pregnancy in the USA. Lancet (London, England). 2009;374:451-458.
7. Siston AM, Rasmussen SA, Honein MA, et al. Pandemic 2009 influenza A(H1N1) virus illness among pregnant women in the United States. JAMA. 2010;303(15):1517-1525.
8. Centers for Disease Control and Prevention. Novel influenza A (H1N1) virus infection in three pregnant women—United States, April–May 2009. MMWR Morb Mortal Wkly Rep. 2009;58:497-500.
9. World Health Organization. Vaccines against influenza WHO position paper—November 2012. Relevé Epidémiologique Hebdomadaire. 2012;87:461-476.
10. Ortiz JR, Perut M, Dumolard L, et al. A global review of national influenza immunization policies: analysis of the 2014 WHO/UNICEF Joint Reporting Form on immunization. Vaccine. 2016;34(45):5400-5405.
11. Feng L, Yang P, Zhang T, et al. Technical guidelines for the application of seasonal influenza vaccine in China (2014–2015). Hum Vaccin Immunother. 2015;11(8):2077-2101.
12. Chen L, Zhou S, Zhang Z, et al. Cohort profile: China respiratory illness surveillance among pregnant women (CRISP), 2015–2018. BMJ Open. 2018;8(4):e019709.
13. Song Y, Zhang T, Chen L, et al. Increasing seasonal influenza vaccination among high risk groups in China: do community healthcare workers have a role to play? Vaccine. 2017;35(33):4060-4063.
14. Yuen CYS, Dodgson JE, Tarrant M. Perceptions of Hong Kong Chinese women toward influenza vaccination during pregnancy. Vaccine. 2016;34(1):33-40.
15. Chinese Pharmacopoeia Commission. Pharmacopoeia of the People’s Republic of China; 2015.
16. Zhou S, Greene CM, Song Y, et al. Review of the status and challenges associated with increasing influenza vaccination coverage among pregnant women in China. Hum Vaccin Immunother. 2019;1-10.
17. Chen L, Zhang J, Zu R, et al. Influenza-related knowledge, attitudes, and practices among pregnant women: a cross-sectional study in Suzhou, China. Options VIII for the Control of Influenza Cape Town, South Africa: ISIRV. 2013;99.
18. Suzhou Statistic Bureau. Suzhou City Economic and Social Development Statistical Year Book; 2015.
19. Yu H, Alonso WJ, Feng L, et al. Characterization of regional influenza seasonality patterns in China and implications for vaccination strategies: spatio-temporal modeling of surveillance data. PLoS Med. 2013;10(11):e1001552.
20. Suzhou Health Bureau. Public Health Statistic Report in Suzhou in 2016; 2016.
21. National Health and Family Planning Committee. National Influenza Surveillance Protocol; 2010.
22. Naleway AL, Ball S, Kwong JC, et al. Estimating vaccine effectiveness against hospitalized influenza during pregnancy: multicountry protocol for a retrospective cohort study. JMIR Res Protoc. 2019;8(1):e11333.
23. Katz MA, Gessner BD, Johnson J, et al. Incidence of influenza virus infection among pregnant women: a systematic review. BMC Pregnancy Childbirth. 2017;17(1):192.
24. Dawood FS, Kittikraisak W, Patel A, et al. Incidence of influenza during pregnancy and association with pregnancy and perinatal outcomes in three middle-income countries: a multisite prospective longitudinal cohort study. Lancet Infect Dis. 2020.
25. Chaw L, Kamigaki T, Burmaa A, et al. Burden of influenza and respiratory syncytial virus infection in pregnant women and infants under 6 months in mongolia: a prospective cohort study. PLoS ONE. 2016;11(2):e0148421.
26. Steinhoff MC, Katz J, England JA, et al. Year-round influenza immunisation during pregnancy in Nepal: a phase 4, randomised, placebo-controlled trial. Lancet Infect Dis. 2017;17(9):981-989.
27. Tapia MD, Sow SO, Tamboura B, et al. Maternal immunisation with trivalent inactivated influenza vaccine for prevention of influenza in infants in Mali: a prospective, active-controlled, observer-blind, randomised phase 4 trial. Lancet Infect Dis. 2016;16(9):1026-1035.
28. Madhi SA, Cutland CL, Kuwanda L, et al. Influenza vaccination of pregnant women and protection of their infants. N Engl J Med. 2014;371(10):918-931.
29. Sokolow LZ, Naleway AL, Li DK, et al. Severity of influenza and non-influenza acute respiratory illness among pregnant women, 2010–2012. Am J Obstet Gynecol. 2015;212:202.e1-202.e11.
30. Creanga AA, Johnson TF, Graitcer SB, et al. Severity of 2009 pandemic influenza A (H1N1) virus infection in pregnant women. Obstet Gynecol. 2010;115(4):717-726.
31. Prasad N, Huang QS, Wood T, et al. Influenza-associated outcomes among pregnant, postpartum, and nonpregnant women of reproductive age. J Infect Dis. 2019;219(12):1893-1903.
32. Regan AK, Moore HC, Sullivan SG, De NK, Effler PV. Epidemiology of seasonal influenza infection in pregnant women and its impact on birth outcomes. Epidemiol Infect. 2017;1.
33. Tokars JI, Olsen SJ, Reed C. Seasonal incidence of symptomatic influenza in the United States. Clin Infect Dis. 2018;66(10):1511-1518.
34. Reed C, Kim IK, Singleton JA, et al. Estimated influenza illnesses and hospitalizations averted by vaccination among pregnant, postpartum, and nonpregnant women of reproductive age. J Infect Dis. 2019;219(12):1893-1903.
35. Chinese Influenza Weekly Report. Chinese National Influenza Center; 2019.
36. National Health Commission of the PRC. Notice on the prevention and treatment of influenza in 2018. 2018.
37. Li R, Xie R, Yang C, Rainey J, Song Y, Greene C. Identifying ways to increase seasonal influenza vaccine uptake among pregnant women in China: a qualitative investigation of pregnant women and their obstetricians. Vaccine. 2018;36(23):3315-3322.
38. Thompson MG, Li DK, Naleway AL, et al. Factors associated with recruitment, surveillance participation, and retention in an observational study of pregnant women and influenza. BMC Pregnancy Childbirth. 2019;19(1):161.

How to cite this article: Chen L, Zhou S, Bao L, et al. Incidence rates of influenza illness during pregnancy in Suzhou, China, 2015–2018. Influenza Other Respi Viruses. 2022;16(1):14-23. https://doi.org/10.1111/irv.12888